NCT06965231View on ClinicalTrials.gov

Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial

PHASE2RecruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

December 30, 2028

Study Completion Date

March 30, 2029

Conditions
Melanoma of SkinAcral MelanomaStage II Melanoma
Interventions
DRUG

Toripalimab combined with Endostar

"1. Neoadjuvant Phase: 2 doses of toripalimab (240 mg IV, Q2W) before surgery.~2. Surgery: Tumor resection within 2 weeks after the last neoadjuvant dose.~3. Adjuvant Phase: 1) Toripalimab: 240 mg IV every 2 weeks (up to 11 cycles); 2) Endostar: 210 mg (72-hour continuous IV infusion) every 4 weeks (up to 6 cycles)."

Trial Locations (4)

200032

RECRUITING

Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, Shanghai

200081

RECRUITING

Cancer center, Shanghai 411 hospital, China RongTong Medical Healthcare Group Co.Ltd./411 Hospital, Shanghai University, Shanghai

200240

RECRUITING

Department of Surgical Oncology, Fudan University Shanghai Cancer Center Minhang Branch Hospital, Shanghai

200336

RECRUITING

Department of Oncology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
collaborator

Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine

UNKNOWN

collaborator

Shanghai 411 hospital

UNKNOWN

lead

Fudan University

OTHER